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Abstract 
Background 
Delirium among patients in the intensive care unit (ICU) is a common condition associated with 
increased morbidity and mortality. Haloperidol is the most frequently used pharmacologic 
intervention, but its use is not supported by firm evidence. Therefore, we are conducting Agents 
Intervening against Delirium in the Intensive Care Unit (AID-ICU) trial to assess the benefits 
and harms of haloperidol for the treatment of ICU-acquired delirium.  
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Methods 
AID-ICU is an investigator-initiated, pragmatic, international, randomised, blinded, parallel-
group, trial allocating adult ICU patients with manifest delirium 1:1 to haloperidol or placebo. 
Trial participants will receive intravenous 2.5 mg haloperidol three times daily or matching 
placebo (isotonic saline 0.9%) if they are delirious. If needed, a maximum of 20mg/daily 
haloperidol/placebo is given. An escape protocol, not including haloperidol, is part of the trial 
protocol. The primary outcome is days alive out of the hospital within 90 days post-
randomisation. Secondary outcomes are number of days without delirium or coma, serious 
adverse reactions to haloperidol, usage of escape medication, number of days alive without 
mechanical ventilation; mortality, health-related-quality-of-life and cognitive function at 1-year-
follow-up.  
A sample size of 1000 patients is required to detect a 7 day improvement or worsening of the 
mean days alive out of the hospital, type 1 error risk of 5% and power 90%.  
 
Perspective 
The AID-ICU trial is based on gold standard methodology applied to a large sample of 
clinically representative patients and will provide pivotal high-quality data on the benefits and 
harms of haloperidol for the treatment ICU-acquired delirium.  
 
 
1. Introduction 
Delirium is a clinical syndrome diagnosis covering an acute state of organic brain dysfunction. 
Delirium often accompanies severe somatic illness, and typical symptoms comprise acutely 
changing or fluctuating mental status including inattention, disorganized thinking, and an 
altered level of consciousness.1 Clinically, patients may present with or without agitation, 
denoted hyperactive and hypoactive delirium motor subtypes.2 Delirium is a frequent condition 
in the Intensive Care Unit (ICU), with reported incidences varying between 30 to 50% and even 
higher among mechanically ventilated patients.3-5 Delirium is associated with various 
detrimental outcomes, such as increased number of days on mechanical ventilation, increased 
ICU and hospital lengths of stay (LOS), long-term disability and cognitive decline, higher cost 
of care and increased mortality.3,6-10  
Despite of the fact that no intervention to date has proven consistently efficacious,11-14 various 
pharmacological agents are used to intervene against delirium.15,16 According to a recent 
international investigational cohort of patients from 99 ICUs, haloperidol is the most frequently 
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used agent to treat delirium.17 This is in accordance with various international guidelines.18-21 
However, these recommendations are not supported by evidence. Consequently, the Society of 
Critical Care Medicine (SCCM) has changed their guidelines (PADIS Guideline 2013 and 
2018)22,23 and does not recommend haloperidol to treat delirium due to the lack of evidence of 
effect. Nevertheless, this recommendation is based on low quality of evidence due to the 
absence of adequately powered randomized clinical trials (RCTs).  
Conflicting guidelines built on a low level of evidence, a recent overview of reviews finding 
appalling lack of evidence for the use of haloperidol24 and the continued use of pharmacological 
agents, especially haloperidol, to treat delirium reveal an urgent need for an RCT with low risk 
of bias assessing the balance between benefits and harms of haloperidol in adult ICU-patients 
with delirium. Therefore, we are conducting Agents Intervening against Delirium in the 
Intensive Care Unit (AID-ICU) trial.  
 
1.2 Trial hypotheses 
We hypothesise that treatment with haloperidol as compared to placebo in adult delirious ICU-
patients will affect the number of days alive out of the hospital within 90 days post-
randomisation and reduce the duration of delirium in these patients. Furthermore, we expect that 
haloperidol as compared with placebo increases the total number of serious adverse reactions 
(SAR) and the number of SARs per patient.   
 
2. Methods 
This trial protocol was written in accordance with the Standard Protocol Items: 
Recommendation for Interventional Trials (SPIRIT) 2013 statement.25 The SPIRIT checklist is 
presented in Appendix 1. 
 
2.1 Trial design 
The AID-ICU trial is an investigator-initiated, pragmatic, international, randomised, blinded, 
parallel-group, trial allocating adult ICU patients with delirium to 1:1 of haloperidol versus 
placebo. Stratified for trial site and delirium motor subtype (hyperactive or hypoactive) at the time 
of inclusion.  
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2.2 Registration 
The trial was registered at the European Union Clinical Trial Register (EudraCT no. 2017-
003829-15 approved November 30, 2017) and at ClinicalTrials.gov (Identifier 
no.NCT03392376 January 8, 2018) before inclusion of the first patient.    
 
2.3 Setting 
European ICUs admitting adult patients. A complete list of participating trial sites is available at 
ClinicalTrials.gov (Identifier no. NCT03392376).  
 
2.4 Study population 
Inclusion criteria 
Adult patients acutely admitted to the ICU with delirium diagnosed using a validated screening 
tool, i.e. the Confusion Assessment Method – Intensive Care Unit (CAM-ICU)26 or the 
Intensive Care Delirium Screening Checklist (ICDSC)27, are eligible for inclusion.  
 
Exclusion criteria 
Patients will be excluded from the trial if they meet one of the following exclusion criteria: (1) 
known contraindications to haloperidol, (2) habitual treatment with any antipsychotic 
medication or treatment with antipsychotics in the ICU prior to screening, (3) permanently 
incompetent (e.g. dementia, mental retardation), (4) delirium assessment non-applicable 
(language barriers, serious auditory or visual disabilities), (5) withdrawal from active therapy or 
brain death, (6) fertile women (< 50 years) with positive urine human chorionic gonadotropin 
(hCG) or plasma-hCG, (7) consent according to national regulations not obtainable, (8) patients 
under coercive measures by regulatory authorities, or (9) patients with alcohol-induced delirium 
(delirium tremens). 
 
2.5 Screening  
All patients admitted to a participating clinical trial site is considered for participation. 
Experienced ICU nurses screen patients for delirium with a validated screening tool (CAM-ICU 
or ICDSC) at least two times a day. When an adult patient at the ICU is diagnosed with 
delirium, the patient is screened for eligibility of enrolment by local investigators using a central 
web-based screening system (OpenClinica). The distribution of trial participants will be 
displayed in a Consolidated Standards of Reporting Trials (CONSORT) diagram.28  
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2.6 Randomisation  
Eligible patients are randomised 1:1 according to a computer-generated allocation sequence list, 
the stratification variables, and permuted blocks of varying sizes. The allocation sequence list 
will exclusively be known to the data manager at Copenhagen Trial Unit (CTU) and will be 
unknown to the investigators to allow immediate and concealed allocation of trial participants. 
Each trial participant is allocated a unique patient screening number, which will link the patient 
to the allocated trial intervention.  
 
2.7 Trial intervention 
Enrolled patients are randomised to receive either intravenous haloperidol (Haldol, Jannsen-
Cilag, Birkeroed, Denmark) or placebo (Isotonic saline 9 mg/ml) 0.5ml (2.5mg haloperidol or 
matching placebo) three times daily. If needed, additional trial medication may be administered 
up to a maximum dose of 20 mg haloperidol/placebo daily (corresponding to 5 additional 
administrations of 0.5ml of trial medication). In case of incontrollable delirium, trial 
participants may receive escape medication (propofol, benzodiazepines or alfa2-agonists), but 
not haloperidol, as decided by the clinical team.  
The intervention period will be from randomisation until ICU discharge for a maximum of 90 
days. If a trial participant is readmitted to an ICU, participating in the trial, within the 90–day 
intervention period, the intervention will be resumed. 
Trial medication will pause during the intervention period if the patient is delirium-free as 
defined by the pausing criteria: two consecutive negative CAM-ICU or ICDSC (< 4) scores on 
the same day (morning and evening assessment). Delirium screening, data registration and 
follow-up will continue. If a participant again becomes delirious, he/she will resume the 
allocated intervention.  
 
2.8 Outcome measures 
Primary outcome measure  
Number of days alive and out of hospital within 90 days post-randomisation.  
 
Secondary outcome measures  
1. Number of days alive without delirium or coma in the ICU 
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2. Number of patients with one or more SARs to haloperidol and total number of SARs to 
haloperidol 
3. Number of patients using escape medicine and number of days with escape medicine per 
patients 
4. Number of days alive without mechanical ventilation in the 90-day period 
5. 1-year mortality post-randomisation 
6. Health-related quality-of-life assessed by EuroQol 5 dimensions 5 level questionnaire and 
EQ visual analogue scale (EQ-5D-5L)29 1-year post-randomisation.   
7. Cognitive function at inclusion assessed by proxy using the Informant Questionnaire for 
Cognitive Decline in the Elderly (IQ-CODE)30, and cognitive function measured using the 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)31 score and 
Trail Making Test A&B32 1-year post randomisation, at selected sites.  
8. A health economic analysis will be performed. The analytic details will be based on the 
result of the trial and specified (cost-effectiveness vs. cost-minimisation analyses). 
Outcomes will be 1-year mortality and Quality Adjusted Life Years (QALYs). The latter 
will be conducted based on EQ-5D-5L. The calculation of QALYs generates a cost-utility 
analysis. 
 
2.9 Blinding 
The allocated trial medication is blinded to the clinical staff, to the patient, the investigators, the 
outcome assessors, the statistician conducting the analyses and the steering committee when 
drafting the abstract for primary publication.  
The Hospital Pharmacy of the Capital Region of Denmark (HP), which holds a Good 
Manufacturing Practice certificate, is responsible for the placebo production, import of the 
investigational medicinal product (IMP) from Jannsen-Cilag A/S, blinding, labelling and 
distribution of IMP and placebo to Danish trial sites. World Currier will handle distribution of 
IMP to international trial sites.    
Haloperidol is contained in liquid form in an ampoule. Placebo will be contained in an identical 
ampoule. The solution of haloperidol is colourless and cannot be visually distinguished from 
isotonic saline. Each ampoule will contain the same volume (1 ml), corresponding to 5 mg 
haloperidol. Three ampoules of either placebo or IMP are packaged in a box with a unique trial 
medication ID. Labelling of ampoules, primary package end secondary package of IMP and 
placebo will be identical and contain the required information of trial drugs.  
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Trained ICU nurses will dispense trial medication through a centralised web-based medication 
dispensation system (Meddis). The system will ensure allocation of the right intervention 
(IMP/Placebo) to the patient by linking trial participant ID to a unique trial medication number 
each time additional trial medication is needed.   
Un-blinding of the intervention may be done if deemed necessary by the clinician or 
investigator for the benefit of the trial participant’s treatment or safety (e.g. suspected 
unexpected serious adverse reaction, (SUSAR)). Furthermore, the data-monitoring and safety 
committee (DMSC) can request un-blinding of the trial, if the interim analysis gives strong 
indications of one intervention being more beneficial or harmful than the other.   
 
2.10 Data registration and monitoring 
Data will be entered into a central web-based electronic case report form (eCRF) using the 
clinical data management system OpenClinica software (OpenClinica, LLC, Waltman, MA 
02451, USA). The eCRF is password protected, encrypted and supported by CTU and allows 
for detailed centralised and decentralised surveillance of data completeness overall and at each 
site. Each participating trial site will only have access to their own data. Details and definitions 
of collected data are presented in Appendix 2.   
The trial will adhere to Good Clinical Practice (GCP) principles.33 Monitoring will follow a 
predefined monitoring plan developed in collaboration with the GCP Unit at University of 
Copenhagen, which will coordinate the monitoring done by local GCP units and/or monitors in 
all Danish regions and participating countries. The coordinating investigator or her delegates 
will do a centralised day-to-day monitoring through the eCRF. 
 
2.11 Safety 
An independent DMSC with two physicians/researchers and a statistician may recommend 
pausing or stopping the trial if continued conduct of the trial clearly compromises patient safety. 
The DMSC charter is presented in Appendix 3.  
 
Patients can be withdrawn from the trial at any time if:  
 A SAR or SUSAR occurs.  
 The responsible physician in conjunction with the sponsor decides it to be in the 
patient’s interest. 
 The patient after inclusion is subject to involuntary hospitalization (coercive measures) 
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 The patient after inclusion develops QTc prolongation (> 500 msec). 
 The trial guardian, patient or next of kin withdraws consent. 
In these cases, data collection will continue, and follow-up will be conducted. The patient will 
remain in the intention-to-treat population if he/she has received the trial medication. 
 
Serious adverse reactions  
Adverse reactions are specified in the summary of product characteristics of haloperidol (Appendix 
4). We consider the following conditions related to the intervention to be SARs:  
 Anaphylactic reaction 
 Agranulocytosis 
 Pancytopenia 
 Ventricular arrhythmia 
 Extrapyramidal symptoms  
 Tardive dyskinesia 
 Malignant neuroleptic syndrome 
 Acute hepatic failure 
SARs will be evaluated and recorded daily in the electronic case report form (eCRF) during the 
ICU stay. The distribution of SARs will be compared by the DMSC at interim and final analyses.   
SUSARs are defined as serious adverse reactions (SARs) not described in the summary of product 
characteristics of haloperidol. Trial investigators will report SUSARs to the sponsor within 24 
hours, further reporting to national health authorities is done by the sponsor within 7 days. On a 
yearly basis the sponsor will conduct a safety report of all reported SARs and SUSARs to the 
Danish Medicines Agency and National Ethics Committee.  
 
2.12 Approvals  
The trial is approved by the Danish Medicines Agency (EudraCT no. 2017-003829-15), the 
Committees on Health Research Ethics in the Zealand Region of Denmark (SJ-646) and the 
Danish Data Protection Agency (REG-169-2017) and by all required authorities in participating 
countries. All patients are enrolled after achievement of consent for participation according to 
national regulations.    
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2.13 Statistics 
A detailed statistical analysis plan will be published before the enrolment of the last trial 
participants.    
The primary analyses will be based on the intention-to-treat population being all randomized 
patients who received trial medication.34 To obtain maximum statistical power, the primary 
outcome will be compared between treatment groups using a likelihood ratio test building on a 
logistic model for mortality and a linear regression model for days alive out of the hospital within 
90 days. Both models will be adjusted for the stratification variables: site and type of delirium at 
randomization (hypo or hyperactive delirium). The likelihood ratio test will produce a single p-
value. The size of the treatment effect will be quantified using raw means in the two groups along 
with confidence intervals for each mean and for the difference derived from the likelihood function 
underpinning the likelihood ratio test. A secondary analysis will be adjusted for the stratification 
variables and other prognostic co-variates and Simplified Mortality Score (SMS-score35) at 
baseline. 
Subgroup analyses of the primary outcome will be performed defined by stratification variables 
(site and delirium motor subtype) and other important baseline variables: surgical admittance 
(yes/no), age (<69 y, ≥69 y36), sex, one or more risk factors of delirium (+/-) and SMS score (<25, 
≥25)).  
Pre-planned sensitivity analyses of the primary outcome include a per-protocol analysis, excluding 
patients with major protocol violations (patients who did not receive the allocated intervention for 
at least two days despite having delirium, patients receiving the allocated intervention for two days 
despite fulfilling pausing criteria (not delirious), treatment with other antipsychotics during ICU 
stay and withdrawal from trial intervention). The sensitivity analyses will be adjusted for 
stratification variables and for other known prognostic co-variates.  
 
Significance 
A two-sided P-value of less than 0.05 or a 95% confidence interval not including 0 for the primary 
outcome will be considered statistically significant. The secondary outcomes will be given with 
99% corresponding to a modified Bonferroni adjustment37,38 and 95% confidence intervals. P-
values will also be provided for the secondary outcomes, but 99% confidence intervals not 
including 1 (for Risk Ratio - RR) or 0 (for Mean Difference -MD) will be considered as definitely 
statistically significant, while 95% confidence intervals not including 1 (for RR) or 0 (for MD) will 
be considered only possibly statistically significant. 
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2.14 Sample size estimation 
A Wilcoxon rank sum test was applied for power calculations as observational data17 on the 
primary outcome showed a non-normal distribution. Assuming that the treatment will a) lower in-
hospital mortality by 15% and b) shift the distribution of ‘days alive out of the hospital at day 90’ 
of the remaining population to the right with a combined effect on the mean of 8% improvement 
and that 500 patients are randomized to each arm, we will have 90% power (=0.1) at the 5% 
(=0.05 two-sided) significance level.  
 
2.15 Interim analysis 
Interim analyses will be conducted after patient no. 500 has been followed for 90 days. The 
independent DMSC will recommend pausing or stopping the trial if group-difference in the 
primary outcome measure, SARs or SUSARs is found at the interim analyses with statistical 
significance levels adjusted according to the LanDeMets group sequential monitoring 
boundaries based on O’Brien Fleming alfa-spending function, or otherwise finds that the 
continued conduct of the trial clearly compromises patient safety.  
 
2.16 Trial organisation and management 
The AID-ICU trial is performed within the Centre for Research in Intensive Care (CRIC), 
Denmark - a national research centre including the CRIC partners: The departments of Intensive 
Care at Copenhagen (Rigshospitalet), Aalborg and Zealand University Hospitals, CTU, The 
Department of Biostatics, University of Copenhagen and VIVE, the Danish Center for Social 
Science Research. 
The Management committee is responsible for the overall management and coordination, which 
will be supervised by the Steering committee. Site investigators will manage and coordinate the 
trial at the sites. The principal investigator is responsible for data collection and maintenance of 
trial documents.   
Co-enrolment of participants in other interventional trials has to be approved by the AID-ICU 
steering committee but is generally appreciated.  
 
2.17 Data sharing 
The trial results will be submitted to a peer-reviewed international clinical journal.   
De-identified data will be made publicly available 12 months after 1-year follow-up of the last 
randomized patient according to the recent ICMJE recommendations.39 All trial documents, 
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including protocol amendments, will be available on the public AID-ICU trial website 
(www.cric.nu/aid-icu).  
 
2.18 Finances 
The AID-ICU trial has received financial support from Innovation Fund Denmark (4108-
00011B), the Regional Medicines Fund, the Zealand Region Research Fund, Intensive Care 
Symposium Hindsgavl and Foghts Foundation. The funding sources have no influence on trial 
design and will have no influences on data collection, analysis or reporting.  
 
3 Discussion 
Intervention 
Haloperidol is presently the most frequently used agent for treatment of delirium in the ICU,17 
although there is very limited evidence to support this practice.12,14,40,41 Recent data raises 
concerns about the potential harmful effects of haloperidol,42-45 which further challenges its 
ongoing use. Haloperidol was chosen as the interventional drug because of the need to establish 
firm evidence about the benefit and harms of this current, widespread intervention against 
manifest delirium in the ICU.  
  
Outcome 
In ICU delirium research core outcome sets (COS) have been called upon, but at the moment 
none exist.46 Outcome measures in ICU delirium research are challenged by the fluctuating 
delirium status over time, the inability to screen comatose patients, the discontinued delirium 
assessment after ICU discharge and a high mortality in ICU patients. A composite outcome of 
death and delirium status – ‘delirium-free days’ has been used in previous studies, however this 
measure does not address the status of coma. This has led to another prevalent outcome measure 
‘delirium and coma free days’.46 Other outcome measures encountered in ICU delirium research 
include ICU or hospital LOS, days on mechanical ventilation, delirium resolution and 
mortality.12 
 
To address the overall benefits and harms of the intervention consistent objective outcome 
measures are preferable. The use of outcome LOS is biased by the competing event of death, as 
in-hospital mortality influences LOS, and confounded by different discharge criteria. We 
choose ‘days alive out of the hospital within 90 days’ as the primary outcome because it not 
only addresses mortality but also includes morbidity (causing prolonged hospitalization or 
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readmissions). The outcome measure is objective, informative, consistent and likely patient-
centered. Furthermore, a composite outcome creates higher event rates minimizing the required 
sample size (n=1000) and thereby also limiting research costs, while still achieving power to 
determine the overall benefits and harms of haloperidol in the treatment of ICU delirium.  
 
Strength  
The AID-ICU trial is an investigator-initiated, international, randomised placebo controlled trial 
of haloperidol, considering rescue use of haloperidol a protocol violation. The trial design is 
based on a stringent methodology, which includes concealed group allocation, blinding to the 
patient, clinical staff, the investigators, the outcome assessors, and the trial statistician. The trial 
is GCP monitored and an independent DMSC will be responsible for the interim analysis. 
Sample size estimations and trial design are based on a recent inception cohort study, yielding 
data from 99 ICUs and 1260 patients worldwide,17 making the trial relevant and representative 
of current practice and survival rates.     
 
Limitations 
The AID-ICU trial requires patients to be delirious to receive trial medication, which is 
challenging, as the delirium may have a fluctuating course. If the patient is diagnosed as 
delirium free (two consecutive negative delirium screenings in the same day) trial medication 
should be paused and resumed if the patient again becomes delirious (one positive delirium 
assessment). Delirium screening is hereby paramount for compliance with the protocol. 
Inconsistent delirium screening may lead to misleading recruitment by possibly overlooking 
hypoactive delirium subtypes and also insufficient pausing/activation of trial medication. 
Delirium screening should be implemented as standard care at the sites participating in the trial.  
Comatose patients, whether intended or unintended, are not assessable for delirium and their 
delirium status in coma is thereby unknown. Patients should generally continue to receive trial 
medication while in coma. However, clinicians shall on a daily basis, if appropriate, ease the 
level of sedation to ensure sufficient level of consciousness to perform delirium screening. In 
case, the coma is suspected to be caused by the trial medication, all other causes should be 
considered and abolished (e.g. level of sedatives, analgesics etc.) before the trial medication is 
paused according to the coma-criteria.      
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4. Perspective  
Encompassing 1000 patients and estimated participation of 20 European ICUs, the AID-ICU 
trial in the ICU aims to give firm evidence on the efficacy and safety of haloperidol in the 
treatment of delirium in the ICU. The trial is conducted with a stringent methodology, which 
complies with international guidelines for clinical trials and good clinical practice. The results 
will be included in a future updated systematic review whereby we aim to achieve established 
knowledge about the effect of haloperidol on delirium in the ICU. 
 
5. Trial status 
The trial is currently recruiting at 13 active trial sites. The first patient was enrolled in June 
2018. Trial status is displayed on the trial website www.cric.nu/aid-icu/. The current protocol is 
version 4.2 dated June 7 2019. Inclusion of patients is expected to end in 2020.  
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